Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Biomea Fusion, Inc. (BMEA) since 2021 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Biomea Fusion, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1840439.
Total stock buying since 2021: $35,904,482.
Total stock sales since 2021: $35,082,644.
Total stock option exercises since 2021: $0.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2024 | 12,509 | $55,364 | 0 | $0 | 0 | $0 |
| 2023 | 400,000 | $12,000,000 | 1,050,000 | $34,286,550 | 0 | $0 |
| 2022 | 45,684 | $552,068 | 69,316 | $796,094 | 0 | $0 |
| 2021 | 1,426,256 | $23,297,050 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2024-06 | 12,509 | $55,364 | 0 | $0 | 0 | $0 |
| 2023-06 | 0 | $0 | 150,000 | $5,184,450 | 0 | $0 |
| 2023-05 | 0 | $0 | 500,000 | $17,028,300 | 0 | $0 |
| 2023-04 | 0 | $0 | 200,000 | $5,823,800 | 0 | $0 |
| 2023-03 | 400,000 | $12,000,000 | 200,000 | $6,250,000 | 0 | $0 |
| 2022-11 | 5,000 | $39,650 | 0 | $0 | 0 | $0 |
| 2022-08 | 30,684 | $425,648 | 0 | $0 | 0 | $0 |
| 2022-07 | 0 | $0 | 34,658 | $388,516 | 0 | $0 |
| 2022-06 | 0 | $0 | 34,658 | $407,578 | 0 | $0 |
| 2022-01 | 10,000 | $86,770 | 0 | $0 | 0 | $0 |
| 2021-09 | 69,316 | $759,702 | 0 | $0 | 0 | $0 |
| 2021-08 | 104,000 | $1,237,368 | 0 | $0 | 0 | $0 |
| 2021-04 | 1,252,940 | $21,299,980 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2024-06-11 | Valle Franco (Chief Financial Officer) | Buy | 12,509 | 4.43 | 55,364 |
| 2023-06-01 | A2a Pharmaceuticals, Inc. (10% Owner) | Sale | 100,000 | 34.56 | 3,456,300 |
| 2023-05-31 | A2a Pharmaceuticals, Inc. (10% Owner) | Sale | 150,000 | 33.81 | 5,071,500 |
| 2023-05-12 | A2a Pharmaceuticals, Inc. (10% Owner) | Sale | 25,000 | 33.84 | 846,000 |
| 2023-05-09 | A2a Pharmaceuticals, Inc. (10% Owner) | Sale | 150,000 | 34.51 | 5,175,750 |
| 2023-05-08 | A2a Pharmaceuticals, Inc. (10% Owner) | Sale | 100,000 | 33.99 | 3,399,300 |
| 2023-04-20 | A2a Pharmaceuticals, Inc. (10% Owner) | Sale | 200,000 | 29.12 | 5,823,800 |
| 2023-03-31 | A2a Pharmaceuticals, Inc. (10% Owner) | Sale | 200,000 | 31.25 | 6,250,000 |
| 2023-03-30 | Cormorant Asset Management, Lp | Buy | 400,000 | 30.00 | 12,000,000 |
| 2022-11-14 | Hitchcock Michael J.m. (Director) | Buy | 5,000 | 7.93 | 39,650 |
| 2022-08-16 | A2a Pharmaceuticals, Inc. (10% Owner) | Buy | 30,684 | 13.87 | 425,648 |
| 2022-07-21 | A2a Pharmaceuticals, Inc. (10% Owner) | Sale | 34,658 | 11.21 | 388,516 |
| 2022-06-24 | A2a Pharmaceuticals, Inc. (10% Owner) | Sale | 34,658 | 11.76 | 407,578 |
| 2022-01-14 | Valle Franco (Chief Financial Officer) | Buy | 10,000 | 8.68 | 86,770 |
| 2021-09-17 | A2a Pharmaceuticals, Inc. (10% Owner) | Buy | 34,658 | 10.96 | 379,851 |
| 2021-09-17 | Stergiopoulos Sotirios (Director) | Buy | 34,658 | 10.96 | 379,851 |
| 2021-08-23 | Butler Thomas Andrew (CEO) | Buy | 24,000 | 13.20 | 316,872 |
| 2021-08-23 | Erdtmann Rainer M (President & COO) | Buy | 24,000 | 13.20 | 316,872 |
| 2021-08-18 | Butler Thomas Andrew (CEO) | Buy | 14,000 | 10.77 | 150,738 |
| 2021-08-18 | Erdtmann Rainer M (President & COO) | Buy | 14,000 | 10.77 | 150,738 |
| 2021-08-17 | Butler Thomas Andrew (CEO) | Buy | 14,000 | 10.79 | 151,074 |
| 2021-08-17 | Erdtmann Rainer M (President & COO) | Buy | 14,000 | 10.79 | 151,074 |
| 2021-04-20 | Cormorant Asset Management, Lp | Buy | 900,000 | 17.00 | 15,300,000 |
| 2021-04-15 | Butler Thomas Andrew (CEO) | Buy | 176,470 | 17.00 | 2,999,990 |
| 2021-04-15 | Erdtmann Rainer M (President & COO) | Buy | 176,470 | 17.00 | 2,999,990 |
Insider trading activities including stock purchases, stock sales, and option exercises of BMEA listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Biomea Fusion, Inc. (symbol BMEA, CIK number 1840439) see the Securities and Exchange Commission (SEC) website.